In addition, ERBB2 mutations have been acquired in ER+ metastatic breast cancer under the selective pressure of endocrine therapies resulting in treatment resistance (Razavi et al. 2018, Nayar et al. 2019, Bose & Ma 2021). This evidence concerns the gene ESR1 and breast cancer.